This excerpt taken from the NVS 6-K filed Jul 19, 2007.
Note: All growth figures refer to year-to-date worldwide sales growth in local currencies
Novartis has received seven major new regulatory approvals for pharmaceuticals in the US and Europe since the start of 2007, making significant progress in delivering a wave of new medicines many with first-in-class status addressing significant medical needs.
These include the approval and launch of the high blood pressure medicine Tekturna/Rasilez in the US, with a launch in Europe anticipated soon. Exforge was launched in the US three months ahead of schedule and also in Europe. Others approved and launched in the first half were Aclasta/Reclast in the US for Pagets disease, the blindness therapy Lucentis in Europe and Sebivo in Europe and China for hepatitis B. Exelon Patch won US approval in July as the first skin patch therapy for Alzheimers disease and Parkinsons disease dementia.
A review of the leading marketed pharmaceutical products follows: